Hyperion Asset Management Ltd Purchases 48,015 Shares of Intuitive Surgical, Inc. $ISRG

Hyperion Asset Management Ltd grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 28.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 218,646 shares of the medical equipment provider’s stock after purchasing an additional 48,015 shares during the period. Intuitive Surgical comprises about 2.7% of Hyperion Asset Management Ltd’s portfolio, making the stock its 13th largest position. Hyperion Asset Management Ltd owned about 0.06% of Intuitive Surgical worth $97,785,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Intuitive Surgical by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock worth $15,026,776,000 after purchasing an additional 263,828 shares in the last quarter. State Street Corp increased its stake in Intuitive Surgical by 1.2% in the 2nd quarter. State Street Corp now owns 15,552,203 shares of the medical equipment provider’s stock valued at $8,451,223,000 after buying an additional 182,871 shares during the last quarter. Capital World Investors lifted its position in shares of Intuitive Surgical by 1.5% during the 3rd quarter. Capital World Investors now owns 7,728,492 shares of the medical equipment provider’s stock worth $3,456,223,000 after buying an additional 116,034 shares in the last quarter. Norges Bank bought a new position in shares of Intuitive Surgical during the 2nd quarter worth approximately $2,569,260,000. Finally, Invesco Ltd. boosted its stake in shares of Intuitive Surgical by 4.8% in the 2nd quarter. Invesco Ltd. now owns 4,421,133 shares of the medical equipment provider’s stock worth $2,402,488,000 after buying an additional 201,159 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ISRG shares. TD Cowen raised Intuitive Surgical to a “strong-buy” rating in a report on Tuesday, January 27th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Intuitive Surgical in a report on Monday, December 29th. Barclays set a $712.00 price objective on Intuitive Surgical and gave the stock an “overweight” rating in a research report on Monday, January 26th. Argus decreased their target price on Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Finally, Evercore lowered their target price on Intuitive Surgical from $580.00 to $550.00 and set an “in-line” rating on the stock in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $615.86.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: FDA clearance expands da Vinci 5 into cardiac surgery, opening a much larger long-term TAM (management cites a jump from ~17k to ~160k addressable procedures in cleared markets) — a multi-year growth driver for procedure volume and consumables. Read More.
• Positive Sentiment: Completed acquisition of Southern Europe distributor businesses (Italy, Spain, Portugal) shifts da Vinci and Ion sales to direct operations — should improve control of regional sales/service and capture margin/recurring revenue over time. Read More.
• Positive Sentiment: Sell-side momentum: Citigroup upgraded ISRG to Buy and several analysts maintain bullish price targets, supporting upside thesis and sentiment. Read More.
• Positive Sentiment: Recent Q4 results beat consensus (strong revenue and EPS growth), reinforcing recurring-consumables revenue and the upgrade cycle for da Vinci systems. Read More.
• Neutral Sentiment: Analyst consensus shows meaningful upside (Zacks highlights ~29.7% average target upside), but that depends on execution and multiple expansion remaining intact. Read More.
• Neutral Sentiment: Long-form bullish pieces reiterate a multi-year growth story from da Vinci 5, Ion and software/services but don’t change near-term valuation concerns. Read More.
• Negative Sentiment: Cybersecurity incident (phishing-linked breach affecting internal systems) is the immediate catalyst for the share decline — investors will watch for customer impact, data exposure, and remediation costs. Read More.
• Negative Sentiment: Insider selling (recent EVP share sales) and management guidance calling for a deceleration in worldwide da Vinci procedure growth in 2026 could pressure near-term sentiment and valuation. Read More. • Read More.

Insider Activity

In other news, Director Gary S. Guthart sold 24,500 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $530.10, for a total value of $12,987,450.00. Following the sale, the director owned 3,694 shares of the company’s stock, valued at $1,958,189.40. The trade was a 86.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Mark Brosius sold 2,362 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $498.68, for a total transaction of $1,177,882.16. Following the sale, the senior vice president owned 3,554 shares in the company, valued at $1,772,308.72. The trade was a 39.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 32,943 shares of company stock valued at $17,279,568. 0.70% of the stock is currently owned by corporate insiders.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $472.16 on Monday. The stock has a market capitalization of $167.68 billion, a PE ratio of 59.84, a P/E/G ratio of 3.64 and a beta of 1.66. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $603.88. The business’s fifty day moving average price is $513.26 and its 200-day moving average price is $512.96.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, topping the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The company had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. During the same quarter last year, the firm posted $2.21 EPS. The firm’s revenue for the quarter was up 18.8% on a year-over-year basis. As a group, equities analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.